BioSpace News Archive

On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the “Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases” at the 2024 Global Rare Disease Research Symposium and the 2nd China Rare Disease Research and Translational Medicine Conference.

The Kleine-Levin Syndrome Foundation announced the appointment of Jason Fisher as its first executive director.

Sermonix Pharmaceuticals Inc. today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO). ASCO 2024 will be held May 31-June 4, 2024, at McCormick Place in Chicago.

Biotricity Inc. is thrilled to announce plans for a revolutionary direct-to-consumer program, HeartSecure, to support the 127M Americans at risk for heart disease.

UFC®, the world’s premier mixed martial arts organization, and American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (Aires Tech or Aires), a pioneer in cutting-edge technology designed to protect against electromagnetic radiation and optimize human health, today announced a new global marketing partnership that will showcase Aires Tech branding within UFC’s biggest events.

Q1 2024 Revenue Increased 147% Year-over-Year to US$5.34 Million Exceeding Previous Guidance

The Maryland Stem Cell Research Commission announces the release of Requests for Applications for the Maryland Stem Cell Research Fund’s first funding cycle of fiscal year 2025.

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.

Calliditas Therapeutics AB, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of full marketing authorisation for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy.

InnoVoyce today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the VYLO™ Laser System.